Brandname drug bioequivalence
House Government Operations/Intergovernmental Relations Subcommittee Chairman Weiss (D-N.Y.) asked FDA for inspection reports that were conducted in the last two years and contain bioequivalence analyses. In the Sept. 25 request, Weiss specified that he wanted reports on "non-generic, brandname pharmaceuticals." FDA has not yet responded.
You may also be interested in...
Company is confident that data readout from pivotal trial could be ready before the end of 2020.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Cognoa said it will submit its AI-powered digital app for early detection of autism for de novo clearance with the US FDA. See what the company’s senior medical director of clinical adoption said about it here.